Nevertheless, this success cannot be replicated in pancreatic cancer because multiple phase III trials with anti-VEGF agents have failed to increase the overall survival of advanced pancreatic cancer patients compared to chemotherapy alone [114]. Here, VEGFA is linked to pancreatic neoplasm.